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Abstract
 
Although DQA1
 
*
 
0301/DQB1
 
*
 
0302 is the human histocompatibility leukocyte antigen (HLA)
class II gene most commonly associated with human type 1 diabetes, direct in vivo experimen-
tal evidence for its diabetogenic role is lacking. Therefore, we generated C57BL/6 transgenic
mice that bear this molecule and do not express mouse major histocompatibility complex
(MHC) class II molecules (DQ8
 
1
 
/mII
 
2
 
). They did not develop insulitis or spontaneous diabe-
tes. However, when DQ8
 
1
 
/mII
 
2
 
 mice were bred with C57BL/6 mice expressing costimula-
tory molecule B7-1 on 
 
b
 
 cells (which normally do not develop diabetes), 81% of the DQ8
 
1
 
/
mII
 
2
 
/B7-1
 
1
 
 mice developed spontaneous diabetes. The diabetes was accompanied by severe
insulitis composed of both T cells (CD4
 
1
 
 and CD8
 
1
 
) and B cells. T cells from the diabetic
mice secreted large amounts of interferon 
 
g
 
, but not interleukin 4, in response to DQ8
 
1
 
 islets
and the putative islet autoantigens, insulin and glutamic acid decarboxylase (GAD). Diabe-
tes could also be adoptively transferred to irradiated nondiabetic DQ8
 
1
 
/mII
 
2
 
/B7-1
 
1
 
 mice.
In striking contrast, none of the transgenic mice in which the diabetes protective allele
(DQA1
 
*
 
0103/DQB1
 
*
 
0601, DQ6 for short) was substituted for mouse MHC class II molecules
but remained for the expression of B7-1 on pancreatic 
 
b
 
 cells (DQ6
 
1
 
/mII
 
2
 
/B7-1
 
1
 
) developed
diabetes. Only 7% of DQ
 
2
 
/mII
 
2
 
/B7-1
 
1
 
 mice developed diabetes at an older age, and none of
the DQ
 
2
 
/mII
 
1
 
/B7-1
 
1
 
 mice or DQ8
 
1
 
/mII
 
1
 
/B7-1
 
1
 
 mice developed diabetes. In conclusion,
substitution of HLA-DQA1
 
*
 
0301/DQB1
 
*
 
0302, but not HLA-DQA1
 
*
 
0103/DQB1
 
*
 
0601, for
murine MHC class II provokes autoimmune diabetes in non–diabetes-prone rat insulin pro-
moter (RIP).B7-1 C57BL/6 mice. Our data provide direct in vivo evidence for the diabeto-
genic effect of this human MHC class II molecule and a unique “humanized” animal model of
spontaneous diabetes.
Key words: type 1 diabetes • animal model • human MHC molecules • transgenic mice
 
Introduction
 
Like many autoimmune diseases, type 1 diabetes is associ-
ated with genes encoding the MHC (1), particularly the
class II molecule DQA1
 
*
 
0301/DQB1
 
*
 
0302 (DQ8 for
short) in humans and its mouse homologue I-A
 
g7
 
 in the
nonobese diabetic (NOD)
 
1
 
 mouse (2, 3). A common fea-
ture of both DQA1
 
*
 
0301/DQB1
 
*
 
0302 and I-A
 
g7
 
 mole-
cules is the expression of a non-aspartic acid residue at posi-
tion 57 of the 
 
b
 
 chain. However, if the amino acid at this
residue is a charged residue, aspartic acid, then the allele has
a protective effect (4–6). Studies also suggest that the simul-
taneous presence of an arginine residue at position 52 on
DQA1 chain and the absence of aspartate at position 57 on
the DQB1 chain further increase susceptibility to the dis-
ease (7). Although the importance of I-A
 
g7
 
 in the develop-
ment of murine diabetes has been unequivocally established
 
in vivo, the role of DQA1
 
*
 
0301/DQB1
 
*
 
0302 in human dis-
ease development is mostly, if not totally, derived indirectly
from genetic association analysis. Transgenic mice that
carry only human MHC class II DQA1
 
*
 
0301/DQB1
 
*
 
0302
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molecules and are deficient in murine MHC class II molecules
(DQ8
 
1
 
/mII
 
2
 
) have been generated recently (8–11). How-
ever, in studies of diabetes they have been mainly used to
identify T cell determinants of pancreatic 
 
b
 
 cell autoantigens
(8, 10, 11). In no case did these transgenic mice (HLA-DQ8
and/or HLA-DR4) develop diabetes spontaneously, even if
they were expressed on the NOD genetic background (11).
Our DQ8
 
1
 
/mII
 
2
 
 mice were bred onto the C57BL/6
genetic background to maintain the specific deficiency of
murine MHC class II (as C57BL/6 mice do not express
MHC class II I-E molecules, the homologue of HLA-DR),
thereby allowing us to more specifically assess the influence
of this DQ molecule without the potential influence of the
many other diabetes susceptibility genes present in NOD
mice (12). However, DQ8
 
1
 
/mII
 
2
 
 mice do not develop
spontaneous insulitis and/or diabetes (9). To investigate if
we could break the tolerance exhibited by these mice by
locally providing the costimulatory signal B7-1, we gener-
ated DQ8
 
1
 
/mII
 
2
 
/rat insulin promoter (RIP).B7-1 mice
by breeding DQ8
 
1
 
/mII
 
2
 
 mice with RIP.B7-1 mice (also
on C57BL/6 genetic background) (13). These RIP.B7-1
mice that carry murine MHC class II I-A
 
b
 
 molecules do not
normally develop diabetes (13). Our study shows that
when murine MHC class II I-A
 
b
 
 molecules are replaced by
human DQA1
 
*
 
0301/DQB1
 
*
 
0302 molecules, this is suffi-
cient to provoke autoimmune diabetes in the majority of
non–diabetes-prone RIP.B7-1 C57BL/6 mice. Moreover,
when the disease susceptibility allele DQ8 was replaced by the
disease protective allele DQ6, i.e., DQA1
 
*
 
0103/DQB1
 
*
 
0601
(which does not have an arginine residue at position 52 on
the DQA1 chain and does have an aspartate at position 57
on the DQB1 chain), the mice developed neither insulitis
nor diabetes. These data provide direct in vivo evidence for
the diabetogenic effect of HLA-DQ8 molecules and offer, for
the first time, a “humanized” animal model of spontaneous
diabetes.
 
Materials and Methods
 
Generation of DQ
 
1
 
/mII
 
2
 
/RIP.B7-1 Transgenic Mice.
 
HLA-
DQA1
 
*
 
0301/DQB1
 
*
 
0302 transgenic, murine MHC class II mole-
cule–deficient C57BL/6 mice (9) were bred with RIP.B7-1 trans-
genic C57BL/6 mice (13) to generate DQ8
 
1
 
/mII
 
2
 
/RIP.B7-1
transgenic mice. F1 offspring of this mating were screened for
DQA1
 
*
 
0301/DQB1
 
*
 
0302 expression by flow cytometric analysis
of PBLs. RIP.B7-1 transgene was screened for by PCR using
genomic DNA isolated from mouse tail biopsy as described pre-
viously (14). DQ8
 
1
 
/RIP.B7-1
 
1
 
 mice were selected and inter-
crossed to generate DQ8
 
1
 
/mII
 
2
 
/RIP.B7-1 mice. The expression of
the DQ8 transgene and murine class II I-A
 
b
 
 molecules was screened
for by flow cytometric analysis of PBLs, and the RIP.B7-1 trans-
gene was screened for by PCR. DQ8 and RIP.B7-1 double
transgene positive and I-A
 
b
 
 negative (DQ8
 
1
 
/mII
 
2
 
/RIP.B7-1)
mice were used for further breeding to obtain DQ8 transgene
homozygosity (9). HLA-DQA1
 
*
 
0103/DQB1
 
*
 
0601 transgenic mice
(also deficient for murine MHC class II molecules) were back-
crossed from C57BL/10 (8) to C57BL/6 background and then
bred with RIP.B7-1 transgenic C57BL/6 mice. The identical
breeding and screening strategy as that for the DQ8 mice was
 
then used for generating DQ6
 
1
 
/mII
 
2
 
/RIP.B7-1 transgenic
mice. DQ
 
2
 
/mII
 
2
 
/RIP.B7-1
 
2
 
, DQ8
 
1
 
/mII
 
2
 
/RIP.B7-1
 
2
 
, DQ6
 
1
 
/
mII
 
2
 
/RIP.B7-1
 
2
 
 transgenic mice, and DQ
 
2
 
/mII
 
1
 
/RIP.B7-1
 
1
 
mice were used as control groups derived from the above breed-
ings. All of the mice used in this study were littermates derived
from the same breeders.
 
Proliferation and Cytokine Assays.
 
Splenocytes (2 
 
3 
 
10
 
5
 
/well)
from diabetic or nondiabetic mice were assayed for antigenic re-
sponse against putative 
 
b
 
 cell autoantigens as described previously
(9). Secreted cytokine proteins from those responses were mea-
sured by ELISA using mAbs and recommended protocols (9;
PharMingen).
 
Adoptive Transfer Experiments.
 
Mice used for these experiments
were irradiated (600 rads) 1 d before the adoptive transfer. Dia-
betic DQ8
 
1
 
/mII2/RIP.B7-1 splenocytes were injected intrave-
nously into the recipients (107/recipient). One group of mice was
injected (7 3 106/recipient) with column-purified CD81 diabetic
DQ81/mII2/RIP.B7-1 splenocytes (.93% purity; Pierce Chemi-
cal Co.). All of the mice were monitored for glycosuria, and the
experiments were terminated 8 wk after adoptive transfer unless
the mice developed diabetes, which was confirmed by blood glu-
cose, and they were killed immediately.
Immunohistology. Pancreas, kidney, liver, and salivary gland
from all of the mice used in this study were examined by immu-
nohistochemistry as described previously (14).
Results
High Incidence of Spontaneous Diabetes Development in
DQ81/mII2/RIP.B7-1 Mice. We recently showed that the
DQ81/mII2 C57BL/6 mice could generate specific im-
mune responses towards putative b cell autoantigens upon
immunization (9). However, they did not develop sponta-
neous insulitis and/or diabetes (9). To investigate if the tol-
erance exhibited by these mice could be altered by provid-
ing the costimulatory signal B7-1 locally, we created DQ81/
mII2/RIP.B7-1 mice by breeding DQ81/mII2 mice with
RIP.B7-1 mice (also on C57BL/6 genetic background) that
only very rarely develop diabetes (13). In striking contrast
to RIP.B7-1 mice carrying murine MHC class II I-Ab mole-
cules, substitution of human DQA1*0301/DQB1*0302 mol-
ecules caused RIP.B7-1 mice to develop diabetes, which
appeared equally in both sexes (Fig. 1 A). Over 80% (17/
21) of DQ81/mII2/RIP.B7-1 mice developed spontaneous
diabetes beginning at z4 mo of age. On the other hand,
only 1 of 15 (6.7%) DQ82/mII2/RIP.B7-1 mice (between 9
and 10 mo of age) and none of the DQ81/mII1/RIP.B7-1
mice (0/17) developed spontaneous diabetes (Fig. 1 A). More-
over, none of the DQ82/mII1/RIP.B7-1 mice (0/18) be-
came diabetic after 10 mo of observation, supporting previ-
ous observations in C57BL/6.RIP.B7-1 mice (13).
Protection of Diabetes Development in DQ61/mII2/RIP.B7-1
Mice. To confirm that the diabetogenic effect seen in DQ81/
mII2/RIP.B7-1 mice was specific for HLA-DQ8 molecules,
we generated HLA-DQA1*0103/DQB1*0601 transgenic
mice that expressed B7-1 molecules on pancreatic b cells
and were murine I-Ab deficient (DQ61/mII2/RIP.B7-1).
It is interesting that none of the DQ61/mII2/RIP.B7-1
mice (n 5 16, 9 female and 7 male) developed diabetes by 9
mo of age when the experiment was terminated (Fig. 1 B).99 Wen et al.
As was observed in the DQ8 experiments, 1 out of 12 DQ62/
mII2/RIP.B7-1 mice (8.3%) became diabetic at nearly 9 mo
of age (Fig. 1 B), whereas none of the DQ61/mII1/RIP.B7-1
mice (0/9) developed diabetes.
Diabetes Could Be Transferred by Diabetic DQ81/mII2/
RIP.B7-1 Splenocytes. Adoptive transfer experiments showed
that diabetes in DQ81/mII2/RIP.B7-1 mice was autoim-
mune mediated. Splenocytes (depleted of erythrocytes) from
diabetic DQ81/mII2/RIP.B7-1 mice were adoptively trans-
ferred into either DQ81 or DQ82 irradiated recipients (8–10
wk of age; Fig. 2). Diabetes appeared in 78% of the DQ81/
mII2/RIP.B7-1 recipients (7/9) beginning at 3 wk after
cell transfer, but in only 2 of 8 DQ82/mII2/RIP.B7-1 re-
cipients between 6 and 8 wk after adoptive transfer. In
contrast, none of the RIP.B7-1 transgene-negative recipi-
ents, either DQ81/mII2 or DQ82/mII2, developed diabe-
tes 8 wk after the cell transfer (Fig. 2). To ascertain that the
diabetes, developed either spontaneously or after adoptive
transfer, was not primarily CD8 mediated, since two “odd”
mice became diabetic in both experiments, we performed
another group of adoptive transfers using purified CD8 T
cells derived from diabetic DQ81/mII2/RIP.B7-1 spleno-
cytes. None of the recipients (DQ81/mII2/RIP.B7-1; n 5
3) developed diabetes 8 wk after the transfer when the ex-
periment was terminated (Fig. 2), supporting a key role for
the HLA-DQA1*0301/DQB1*0302 molecules and CD4
T cells selected by the molecules in this diabetic model.
Heavy Lymphocyte Infiltration and Upregulation of Adhesion
Molecule in Diabetic DQ81/mII2/RIP.B7-1 Mice. Pancreata
from mice that developed diabetes either spontaneously or via
adoptive transfer showed a profound effect of DQA1*0301/
DQB1*0302 on lymphocytic infiltration. Unlike NOD mice,
in which the islet infiltrates comprise CD41 T cells and B2201
B cells, with fewer CD81 T cells, the islet infiltrates from
diabetic DQ81/mII2/RIP.B7-1 mice contained CD81 T
cells and B2201 B cells, with fewer CD41 T cells (Fig. 3,
top), a picture similar to that reported in recent-onset hu-
man type 1 diabetes (15). This is not entirely unexpected,
as the proportion of CD81 and CD41 (selected by the ex-
pression of HLA-DQ molecules) T cells in DQ81/mII2/
RIP.B7-1 mice is z70 and 30%, respectively, of total CD31
T cells (9). However, the TCR repertoire, as analyzed by a
panel of mAbs against 15 different TCR Vb gene products,
was normal in these mice (9). In contrast to the islet infil-
trates of diabetic DQ81/mII2/RIP.B7-1 mice, the two dia-
betic DQ2/mII2/RIP.B7-1 mice showed heavy islet infil-
tration by CD81 T cells and fewer B2201 B cells (data not
shown). As expected, CD41 T cells were absent. Thus, the
larger number of B2201 B cells infiltrating the islets of
DQ81/mII2/RIP.B7-1 mice was probably recruited by
DQA1*0301/DQB1*0302-selected CD41 T cells.
In striking contrast, pancreata from DQ61/mII2/RIP.B7-1
mice, which were diabetes free, exhibited completely normal
islets (Fig. 3, bottom).
Optimal T cell activation requires additional ligand in-
teractions (16, 17). B7-1– or intracellular adhesion mole-
cule (ICAM)-1–transfected fibroblasts or insect cells, acting
as APCs, induce naive T cells to proliferate and secrete
Figure 1. Development of diabe-
tes spontaneously in HLA-DQ
transgenic mice. (A) Spontaneous
diabetes in DQ8 experiments. Six
groups of mice were used in the
study as indicated. Number of mice
per group was as follows: n 5 21
(10 female, 11 male) DQ81/mII2/
B71; n 5 15 (8 female, 7 male)
DQ82/mII2/B71; n 5 16 (11 fe-
male, 5 male) DQ81/mII2/B72; n 5
14 (8 female, 6 male) DQ82/mII2/
B72; n 5 17 (6 female, 11 male)
DQ81/mII1/B71; and n 5 12
(9 female, 3 male) DQ81/mII2/B72.
(B) Spontaneous diabetes in DQ6
experiments. Four groups of mice were used in the study as indicated. Number of mice per group was as follows: n 5 16 (9 female, 7 male) DQ61/
mII2/B71; n 5 12 (5 female, 7 male) DQ62/mII2/B71; n 5 9 (4 female, 5 male) DQ61/mII1/B71; and n 5 15 (6 female, 9 male) DQ61/mII2/B72.
Mice were housed under specific pathogen-free conditions. Diabetes was determined by monitoring of urinary glucose and confirmed by blood glucose
(.250 mg/dl).
Figure 2. Adoptively transferred diabetes. 10 3 107 diabetic DQ81/mII2/
B71 splenocytes (depleted red blood cells) were transferred intravenously into
irradiated recipients (as indicated). Diabetes was determined as above. Num-
ber of mice per group was as follows: n 5 9 (4 female, 5 male) DQ81/mII2/
B71; n 5 8 (4 female, 4 male) DQ2/mII2/B71; n 5 3 (male) DQ81/mII2/
B72; n 5 3 (male) DQ82/mII2/B72; and n 5 3 (male) DQ81/mII2/B71*
(these recipients were adoptively transferred with purified CD81 splenocytes
only from diabetic DQ81/mII2/B71 mice).100 Spontaneous Diabetes in HLA-DQ8 Transgenic Mice
small amounts of IL-2 (18, 19). However, when both B7-1
and ICAM-1 are expressed together, IL-2 production and
proliferation are greatly increased, independent of APC
number or antigen concentration (18, 19). Wulfing et al.
(20) recently visualized the kinetic interaction of ICAM-1
with T cells after activation and found that ICAM-1 was
rapidly concentrated on B cells, immediately after TCR–
peptide–MHC engagement, at the interface between the
two cells. Therefore, we examined the expression of ICAM-1
on lymphocytes from DQ81/mII2/RIP.B7-1 mice. As ex-
pected, upregulation of ICAM-1 was greater on both T and
B cells derived from pancreatic lymph nodes than on those
from splenocytes in diabetic mice (data not shown). How-
ever, the highest expression of ICAM-1 in diabetic mice
was found in the islet infiltrates (Fig. 4). In a kinetic study,
we noticed that the upregulation of ICAM-1 occurs before
lymphocyte infiltration (our unpublished data). ICAM-1
expression in mice from nondiabetic control groups, in-
cluding DQ61/mII2/RIP.B7-1 mice, was much lower on
lymphocytes obtained from either spleen or pancreatic lymph
nodes (data not shown) and was undetectable in the islets
(Fig. 4).
Autoreactivity and Th1 Cytokine Production in Diabetic
DQ81/mII2/RIP.B7-1 Mice. We next examined whether
splenocytes from diabetic DQ81/mII2/RIP.B7-1 mice rec-
ognize islets or the putative autoantigens, insulin and/or
GAD (21–25). Like diabetic NOD mice, splenocytes from
diabetic DQ81/mII2/RIP.B7-1 mice showed marked au-
toreactivity. Specific reactivity, albeit moderate (two- to
threefold), was detected toward insulin and DQ81 islets
(Fig. 5 A). However, insulin, DQ1 islets, and GAD stimu-
lated the production of IFN-g (IL-4 secretion was unde-
tectable) (Fig. 5 B). Splenocytes from DQ61/mII2/RIP.B7-1
mice or nondiabetic DQ81/mII2/RIP.B7-1 mice showed
much less autoreactivity, and no response to putative auto-
antigens (insulin and GAD) was observed in these mice (data
not shown). Moreover, no autoreactivity was detected in
DQ2/mII2/RIP.B7-1, DQ81/mII1/RIP.B7-1, and DQ2/
mII1/RIP.B7-1 mice. We also analyzed the TCR Vb usage
from cells derived from diabetic and nondiabetic DQ81/
mII2/RIP.B7-1 mice using a panel of mAbs specific for 15
different TCR Vb molecules; no preferential expansion of
any particular TCR Vb subset in either CD41 or CD81 T
cells was detected. However, higher levels of the early T
cell activation marker CD69 were expressed on CD41 than
on CD81 T cells obtained from diabetic mice (data not
shown). T cells from pancreatic lymph nodes of diabetic
mice secreted IFN-g in response to anti-CD3, insulin, or
GAD65, but a negligible amount of IL-4 (data not shown).
Cytoplasmic cytokine staining in combination with CD4
or CD8 coreceptor staining showed that both CD41 and
Figure 3. Immunohistochemis-
try staining of pancreatic sections
of diabetic DQ81/mII2/B71
mice (top panels, a–c) and diabe-
tes-free DQ61/mII2/B71 mice
(bottom panels, d–f). Islet infil-
trates were stained positive for
CD41 T cells (a), B2201 B cells
(b), and CD81 T cells (c).
Figure 4. ICAM-1 staining of pancreatic sections of nondiabetic (a)
and diabetic (b) DQ81/mII2/B71 mice.101 Wen et al.
CD81 T cells were positive for cytoplasmic IFN-g (data not
shown).
Diabetic DQ81/mII2/RIP.B7-1 Mice Also Suffer from
Sialadenitis. The autoimmune response in NOD mice is
not restricted to islets. NOD mice, for unknown reasons,
also develop autoimmune sialadenitis, which is associated
with a decline in salivary gland function (26–28). This
phenomenon has also been reported in type 1 diabetic pa-
tients. Moreover, a specific autoantibody against a-fodrin,
an important autoantigen in human Sjogren’s syndrome,
was found recently in NOD mice (29). Moreover, the
splenocytes of NOD mice produced Th1-type cytokines
in response to a-fodrin (29). Interestingly, salivary glands
from diabetic DQ81/mII2/B71 mice also exhibited sig-
nificant infiltration, consisting of CD4 and CD8 T lym-
phocytes and, to a lesser extent, B lymphocytes (Fig. 6,
top). The development of diabetes appeared to precede
the development of sialadenitis, as was found in NOD
mice (our unpublished data). In addition, the sialadenitis
was even more severe in DQ81/mII2/B71 mice that de-
veloped diabetes after adoptive transfer (data not shown).
Since B7-1 is expressed in islets and not salivary glands,
this may be explained by the fact that more autoreactive T
cells (specific to the autoantigens shared between pancreas
and salivary gland) were transferred to the recipients.
Sialadenitis was much milder in nondiabetic DQ81/mII2/
RIP.B7-1 mice, and no sialadenitis was found in mice car-
rying other genotypes: DQ81/mII2/B72, DQ2/mII2/
B72, DQ81/mII1/B71, DQ2/mII1/B71, and DQ61/
mII2/B71 (Fig. 6, bottom).
Figure 5. In vitro proliferation (A)
and IFN-g production (B) of diabetic
splenocytes to islets and islet b cell
autoantigens. 2 3 105/well of spleno-
cytes (depleted red blood cells) were
cultured in medium (Click’s contain-
ing 5% heat-inactivated FCS) alone
or with antigens (as indicated). Cy-
tokine production was measured in
the supernatants of the cultures (3 d)
by ELISA.
Figure 6. Staining of frozen sections of
salivary gland from diabetic DQ81/mII2/
B71 mice (top panels, a and b) and normal
DQ61/mII2/B71 mice (bottom panels, c and
d). Lymphocyte infiltrates were stained pos-
itive for CD4 (a and c) and CD8 (b and d)
T cells.102 Spontaneous Diabetes in HLA-DQ8 Transgenic Mice
Discussion
Tolerance to self-antigens is the principal means used by
the immune system to protect against “self-destruction.”
Self-tolerance involves two components: central tolerance
and peripheral tolerance (30–32). High-affinity autoreac-
tive T cells are deleted in the thymus by negative selection,
a mechanism that depends on the affinity/avidity levels of
each molecule in the TCR–MHC–peptide trimolecular
complex (33). However, negative selection is not always
complete: some autoreactive T cells can escape and enter
the peripheral lymphoid organs (34–39). A striking feature
of the MHC class II molecules in NOD mice (I-Ag7) and
the human HLA-DQA1*0301/DQB1*0302 is their low-
affinity binding to antigenic peptides (40–42). Thus, T cells
selected on these MHC molecules could potentially escape
from central tolerance and survive in the periphery. This
characteristic of HLA-DQA1*0301/DQB1*0302 (DQ8)
or I-Ag7 molecules, compared with HLA-DQA1*0103/
DQB1*0601 (DQ6) or I-Ab, may allow more of these cells
to escape. However, current data indicate that the presence
of autoreactive CD4 T cells alone in the periphery is not
sufficient to cause diabetes. Our previous study (9) as well
as many studies from NOD mice (43–47) suggest that both
activated CD4 and CD8 T cells are required for disease to
occur. Autoreactive T cells in the periphery are usually “an-
ergic,” “ignorant,” or “suppressed,” thereby preventing self-
destruction. This may be because most autoantigen-express-
ing tissue cells express low levels of MHC class I and do not
express MHC class II molecules. In addition, they do not
express costimulatory signals that are needed to fully acti-
vate T cells in the periphery. From this perspective, the ini-
tiation of autoimmunity may be largely dependent on the
MHC class I–expressing tissue cells and, in the case of this
study, the expression of appropriate costimulatory mole-
cules on the cells that express autoantigen(s). Using RIP
transgenic mice that express a viral protein on pancreatic b
cells, Ohashi et al. (48) and Oldstone et al. (49) demonstrated
that these transgenic mice did not develop spontaneous di-
abetes even though they had a high frequency of viral (“self”)
reactive T cells in the periphery. However, when these
anti-self (viral) T cells were activated by the local expres-
sion of B7-1 molecule (RIP.B7-1), spontaneous diabetes
was produced (50). Unlike their transgene-encoded self
(viral) model of diabetes, which is triggered by antiviral
CD8-mediated autoimmunity, the b cell expression of B7-1
in our model is not sufficient for spontaneous disease devel-
opment.
Our most striking observation is that the substitution of
human HLA-DQ8 for murine MHC class II molecules
caused RIP.B7-1 mice (on a C57BL/6 genetic background),
which are normally resistant to diabetes, to spontaneously
become diabetic. Moreover, replacement of human HLA-
DQ6 molecules for human HLA-DQ8 molecules in these
mice completely prevented the disease. Similar studies show-
ing that induction of disease depends on the presence of
particular HLA-DQ alleles have been recently reported in
an arthritis model (51, 52). However, in that case, the dis-
ease had to be induced by immunization with collagen (as
an autoantigen) in the presence of CFA.
It should be noted that the B7-1 molecules in our mice
were expressed on pancreatic b cells, which do not nor-
mally express MHC class II molecules (53). Thus, it is likely
that the predominant effect of the RIP.B7-1 transgene was
on CD8 T cells (54). Nonetheless, this CD8 T cell effect is
not sufficient to cause diabetes in mice expressing murine
I-Ab molecules. Their CD4 T cells do not support autoim-
munity, and perhaps even have an inhibitory effect. By re-
placing I-Ab with the human DQ8 molecules, autoreactive
CD4 T cells are selected that can now, in conjunction with
the activated CD8 T cells, cause insulitis and diabetes. The
strongest evidence for the pivotal diabetogenic role of DQ8
molecules in disease development is that the “exchange” of
human DQ8 for human DQ6 molecules abolished sponta-
neous disease development. The result is even more im-
pressive given the fact that the DQ transgene rescues CD4
T cells in these mice to only z30% of the normal level of
CD4 T cells but their effect on the disease susceptibility or
protection is very dominant. In terms of the DQ8 effect,
more complete rescue of CD4 T cells may cause the disease
to develop even earlier. This view is consistent with our
data showing that T cells from the diabetic DQ81/mII2/
B71 mice can recognize DQ81 but not DQ82 islets as well
as naturally processed and expressed autoantigens derived
from pancreatic b cells, such as insulin and GAD.
The mechanism by which CD4 T cells selected on
HLA-DQ8 molecules facilitate the development of diabe-
tes is not clear. It has been reported that apoptosis partici-
pates in the remodeling of the endocrine pancreas in both
rodents (shortly after birth) and humans (55–57). It is possi-
ble that HLA-DQ8–expressing APCs such as dendritic cells
(DCs) take up autoantigens from apoptotic b cells and
present them to T cells. Autoreactive CD4 T cells may rec-
ognize the same autoantigen presented by DCs and be-
come activated. These CD4 T cells could sequentially fur-
ther activate APCs via CD40L–CD40 interactions and
cytokine release in the draining lymph nodes. These acti-
vated DCs could then cross-present antigens to CD8 T
cells (58) as well as to other CD4 T cells, thus amplifying
the self-destructive process. In addition, the CD4 T cells
may facilitate the traffic of CD8 T cells to the pancreatic is-
lets by upregulating ICAM-1/vascular cell adhesion mole-
cule (VCAM). The upregulation of ICAM-1 on both lym-
phocytes infiltrating islets and pancreatic b cells provides
maximal costimulation to the autoreactive T cells, which in
turn further aggravate the autoimmune destruction. It is
also possible that autoreactive CD8 T cells, recognizing islet-
derived peptides directly, and stimulated by the presence of
the RIP.B7-1 molecule, initiate the islet-directed autoim-
mune response. However, this autoimmune response could
not be amplified to become destructive without HLA-DQ8–
restricted CD4 T cell help. Regardless of the precise mech-
anisms involved, our model suggests that HLA-DQ8 mole-
cules play an essential role in the disease development and103 Wen et al.
provides direct in vivo evidence of the importance of hu-
man HLA-DQ8 molecules in autoimmune diabetes. Con-
versely, our model also implies the disease-protective role
of HLA-DQ6. This is the first model demonstrating that
HLA-DQ8 could promote spontaneous diabetes in a dia-
betes-resistant mouse strain. Thus, this partially humanized
transgenic model may offer a more relevant system for (a)
examining the immunopathogenesis of, and (b) testing spe-
cific therapeutic intervention for human type 1 diabetes.
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